Yk 4 279 Clinical Trial

YK4279 was administered with 50 mg/kg five times per week B, RPPA analysis of tumors extracted at day 30 (or sooner if they reached 15 mm in diameter).

Yk 4 279 clinical trial. This lack of racemization within the tumors supports development of the (S)YK4279 for clinical trials rather than the racemic mixture DISCUSSIONWe recognized that the small molecule YK4279 has a chiral center and can be separated into its enantiomers In binding assays and transcriptional assays, (S)YK4279 is active and titrations. Small Molecule Therapeutics An Oral Formulation of YK4279 Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma SalahEddine LamhamediCherradi1, Brian A Menegaz1,Vandhana Ramamoorthy1, Ramani A Aiyer2, Rebecca L Maywald3, Adrianna S Buford1, Dannette K Doolittle4, Kirk S Culotta4, James E O'Dorisio5, and Joseph A Ludwig1. YK4279 is an inhibitor of EWSFLI1 The authors also developed TK216, a firstinclass small molecule being tested in a clinical trial for patients with relapsed or refractory Ewing sarcoma, according to the study In the study, the authors discovered that YK4279 worked well with vincristine to inhibit Ewing sarcoma.

YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 EWSFLI1 is a disordered protein that precludes standard structurebased smallmolecule inhibitor design EWSFLI1 binding to RNA helicase A (RHA) is Clinical trial No clinical data are available currently. Tumors were resected two hours following dosing At that time, there was no (R)YK4279 present in tumor tissues after dosing with (S)YK4279 This lack of racemization within the tumors supports development of the (S)YK4279 for clinical trials rather than the racemic mixture. Tumors were resected two hours following dosing At that time, there was no (R)YK4279 present in tumor tissues after dosing with (S)YK4279 This lack of racemization within the tumors supports development of the (S)YK4279 for clinical trials rather than the racemic mixture.

YK4279 also exhibits dosedependent inhibition in a luciferase reporter assay, induces apoptosis in ESFT cells, and reduces the growth of ESFT orthotopic xenografts Current efforts involve medicinal chemistry and pharmacology studies aimed at advancing an improved analog of YK4279 into clinical trials This study is a pioneering example of. On experimental therapies currently in clinical trial for ≥ thirdline treatment of metastatic refractory and/or relapsed Ewing’s Sarcoma (Table 1) YK4279 YK4279 27 is a small molecule that interacts with RNA Helicase A (RHA, encoded by the DHX9 gene) thereby affecting EWS/ FLI1 signaling activity. An Oral Formulation of YK4279 Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma clinical trials—those with metas tatic disease or rapid tumor recurrence fair poorly.

In advance of anticipated earlyphase human clinical trials, we investigated both de novo and acquired mechanism(s) by which Ewing sarcoma cells evade YK4279mediated cell death Drugresistant clones, formed by chronic in vitro exposure to steadily increased levels of YK4279 , overexpressed cKit, cyclin D1, pStat3(Y705), and PKC isoforms. A YK4279 analog, TK216, is currently in clinical trial With any targeted therapy, there is always the risk that tumors will become resistant and stop responding to treatment Here, we investigated resistance mechanisms to YK4279 (YK) by developing ES cell lines specifically resistant to YK. Furthermore, proving YK4279 has only one functional enantiomer will be helpful in moving this compound towards clinical trials YK4279 is a chiral molecule and the enantiomers were separated.

Its analog, TK216, is currently in clinical trial With any targeted therapy, there is always the risk that tumors will become resistant and stop responding to treatment Here, resistance mechanisms to YK4279 were investigated Interestingly, CD99 was identified as a critical player in Ewing sarcoma resistance to YK4279. The paper was published in Oncotarget in November 13 The biggest remaining hurdle to a human clinical trial is developing a usable formulation This is currently the top priority of the company that is developing YK4279. This lack of racemization within the tumors supports development of the (S)YK4279 for clinical trials rather than the racemic mixture DISCUSSIONWe recognized that the small molecule YK4279 has a chiral center and can be separated into its enantiomers In binding assays and transcriptional assays, (S)YK4279 is active and titrations.

Therapeutic efficacy of YK4279 was proved in in vitro and in vivo models The YK4279 analog TK216 is currently being used in a Phase I clinical trial in patients with relapsed or refractory Ewing’s sarcoma. YK4279 New YK4279 is a potent inhibitor of EWSFLI1 binding to RNA helicase A (RHA) Cisplatin Cisplatin (cisplatinum, cisdiamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells Cisplatin activates ferroptosis and induces autophagy. ETSrelated transcription factors Further analysis reveals that YK4279 induces mitotic arrest in prometaphase, resulting in subsequent cell death Mechanistically, we show that YK4279 inhibits the formation of kinetochore microtubules, with treated cells showing a broad range of abnormalities including.

YK4279 New YK4279 is a potent inhibitor of EWSFLI1 binding to RNA helicase A (RHA) BMH21 New BMH21 is a DNA intercalator, which binds ribosomal DNA and inhibits RNA polymerase I (Pol I) transcription Cisplatin. Case A, YK4–279, has shown in vitro activity against ES,27 and it competes against RNA helicase A’s specific binding site on the EWS–FLI1 protein, which is needed for it to function28 29 TK216 is an analog of YK4–279, which is being tested in a phase Ib clinical trial (NCT) TK216 has shown favorable interim results, including a. Dosing of YK4279 over roughly one month, which led to regression This was the first time ES was modelled in a rat;.

We next established the IC 50 's for YK4279 in a panel of nine neuroblastoma cell lines All these lines were sensitive to YK4279 (Fig 2A), with IC 50 's ranging from 04 to 2 μMThis range is similar to that reported for Ewing's sarcoma cell lines (05–2 μM) In order to further explore the selectivity of YK4279 action, we tested YK4279(R) and YK4279(S) enantiomers. VCR YK4279 75 mg/kg YK4279 75 mg/kg QDx5 VCR 1 mg/kg Q7D Control TK216 Analogue YK 4279 is Synergistic with Vincristine TK216 Inhibits Oncogenic Transcription and Cell Proliferation • Phase 1/2 clinical trial in 3 Parts − Dose Escalation cohorts. We next established the IC 50 's for YK4279 in a panel of nine neuroblastoma cell lines All these lines were sensitive to YK4279 (Fig 2A), with IC 50 's ranging from 04 to 2 μMThis range is similar to that reported for Ewing's sarcoma cell lines (05–2 μM) In order to further explore the selectivity of YK4279 action, we tested YK4279(R) and YK4279(S) enantiomers.

YK4279 is an inhibitor of EWSFLI1 The authors also developed TK216, a firstinclass small molecule being tested in a clinical trial for patients with relapsed or refractory Ewing sarcoma, according to the study In the study, the authors discovered that YK4279 worked well with vincristine to inhibit Ewing sarcoma. Thus, (S)YK4279 as a small molecule drug is ready for continued development towards a firstinhuman, firstinclass, clinical trial INTRODUCTION Ewing Sarcoma (ES) is a rare cancer of bone or soft tissue that affects 3 people per million each year,. Daily enteral administration of YK4279 led to significant delay in Ewing sarcoma tumor growth within a murine model In advance of anticipated earlyphase human clinical trials, we investigated both de novo and acquired mechanism(s) by which Ewing sarcoma cells evade YK4279mediated cell death.

This greatly limits radio and chemotherapeutic options and disease management In the present study, we investigated three patientderived chordoma cell lines to elucidate the molecular mechanism of resis. Daily enteral administration of YK4279 led to significant delay in Ewing sarcoma tumor growth within a murine model In advance of anticipated earlyphase human clinical trials, we investigated both de novo and acquired mechanism (s) by which Ewing sarcoma cells evade YK4279–mediated cell death. There is still much testing that needs to be done before clinical trials involving humans can begin Research into what side effects might occur and how to better administer the drug need to be conducted, but these current results from the mice trials suggest that YK4279 might provide a new treatment for prostate cancer.

By contrast, mice receiving only two weeks of YK4279 lived nearly three times as long “The fact that treated mice did not get sick from the YK4279 gives us an early indication that it might be safe to use in humans, but that is a question that can’t be answered until we conduct clinical trials,” Üren explains. YK4279 is a small molecule that binds to EWSFLI1 and blocks its interaction with DHX9, resulting in growth arrest and apoptosis in ES cells (9) This disruption of protein interaction rather than inhibition of a relatively ubiquitous enzyme is believed to provide relative specificity for cancer cells. 1 An Oral Formulation of YK4279 Preclinical Efficacy and Acquired Resistance Patterns in Ewing’s Sarcoma SalahEddine LamhamediCherradi1, Brian A Menegaz1, Vandhana Ramamoorthy1, Ramani A Aiyer2, Rebecca L Maywald3, Adrianna S Buford1, Dannette K Doolittle4, Kirk S Culotta4, James E O’Dorisio5, & Joseph A Ludwig1 1Sarcoma Medical Oncology, 4Laboratory of Experimental.

Herein, we demonstrate marked preclinical antineoplastic activity of an orally bioavailable formulation of YK4279 (YK) and identify mechanisms of acquired chemotherapy resistance that may be. Toretsky's work on YK4279 led to the eventual development of TK216, a firstinclass small molecule that is now being studied by Oncternal Therapeutics in a clinical trial in patients with. 1 The ETS inhibitors YK4279 and TK216 are novel antilymphoma agents Filippo Spriano 1*, Elaine Yee Lin Chung 1*, Eugenio Gaudio 1, Chiara Tarantelli 1, Luciano Cascione 1,2, Sara Napoli 1, Katti Jessen 3, Laura Carrassa 4, Valdemar Priebe 1, Giulio Sartori 1, Garrett Graham 5, Saravana P Selvanathan 5, Andrea Cavalli 6, Andrea Rinaldi 1, Ivo Kwee 1,2,7, Monica Testoni 1,.

Significant efforts failed to obtain a commercial partner to license YK4279 due to the extraordinarily rare incidence of Ewings sarcoma Therefore, in 14 Dr Toretsky cofounded Tokalas, Inc to advance an analog of YK4279 to a clinical trial that is commencing in the spring of 16. YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 EWSFLI1 is a disordered protein that precludes standard structurebased smallmolecule inhibitor design EWSFLI1 binding to RNA helicase A (RHA) is Clinical trial No clinical data are available currently. YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 EWSFLI1 is a disordered protein that precludes standard structurebased smallmolecule inhibitor design EWSFLI1 binding to RNA helicase A (RHA) is Clinical trial No clinical data are available currently.

Conclusions The ETS inhibitor YK4279 and its clinical derivative TK216 represent a new class of agents with in vitro and in vivo antitumor activity in lymphomas. The other, YK4279, is an experimental drug that targets an abnormality, called a fusion protein, that is commonly found in Ewing sarcoma tumors The researchers’ findings, published October 3 in Science Signaling, showed that, when combined, the two drugs work together to kill more cancer cells than either treatment alone. In advance of anticipated earlyphase human clinical trials, we investigated both de novo and acquired mechanism(s) by which Ewing sarcoma cells evade YK4279mediated cell death Drugresistant clones, formed by chronic in vitro exposure to steadily increased levels of YK4279 , overexpressed cKit, cyclin D1, pStat3(Y705), and PKC isoforms.

Chordoma, a malignant bone cancer, is highly resistant to conventional therapeutic approaches;. Toretsky's work on YK4279 led to the eventual development of TK216, a firstinclass small molecule that is now being studied by Oncternal Therapeutics in a clinical trial in patients with. YK4279 (10 μM) inhibited motility in a scratch assay in highpassage LNCaP cells YK4279 showed antiproliferative activity with the IC50 values of 1 and 8 μM in primary cell lines ES925 and GUES1 YK4279 induced caspase3 activity in four ESFT cell lines (TC32, 573, TC71, and ES925).

YK4279 can also affect other ETS transcription factors, such as ERG and ETV1 in prostate cancer cells (11–14) TK216 is a derivative developed for clinical trials with demonstrated in vitro and in vivo antitumor activity in ES models (15). YK4279 directly inhibits EWSFLI1 Dr Toretsky’s work on YK4279 led to the eventual development of TK216, a firstinclass small molecule that is now being studied by Oncternal Therapeutics in a clinical trial in patients with relapsed or refractory Ewing sarcoma. The small molecule, YK4279, which blocks RHA binding to EWSFLI1 demonstrated decreased cyclin D levels in ES cells Clinical trials using G3139 (genasense) in combination with doxorubicin and cyclophosphamide are ongoing in patients with ES Thus, pharmacologic downregulation of l2 by G3139 may potentially enhance the chemotherapy.

Therapeutic efficacy of YK4279 was proved in in vitro and in vivo models The YK4279 analog TK216 is currently being used in a Phase I clinical trial in patients with relapsed or refractory Ewing’s sarcoma. YK4279 (10 μM) inhibited motility in a scratch assay in highpassage LNCaP cells YK4279 showed antiproliferative activity with the IC50 values of 1 and 8 μM in primary cell lines ES925 and GUES1 YK4279 induced caspase3 activity in four ESFT cell lines (TC32, 573, TC71, and ES925).